By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit

Key Statistics

Ownership: Private

Web Site: Acucela


Company News
Acucela Announces Top-Line Results From Phase 2b/3 Clinical Trial Of Emixustat 5/26/2016 11:32:55 AM
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy 5/9/2016 11:47:40 AM
Acucela To Present At Association for Research in Vision & Ophthalmology 2016 Annual Meeting’s Education Courses In Seattle 4/22/2016 8:22:29 AM
Acucela Announces End Of Treatment Period In Phase 2b/3 Clinical Trial Of Emixustat Hydrochloride 4/19/2016 12:50:52 PM
Acucela Secures Option To Exclusively License Novel Cataract Treatment 3/17/2016 10:00:31 AM
Acucela To Present At The Biotech Showcase 2016 In San Francisco 1/12/2016 9:42:25 AM
Acucela To Present At The Biotech Showcase 2016 In San Francisco 1/11/2016 1:07:12 PM
Acucela Validates Sampling Method That Could Pave Way For More Efficient Clinical Tests 11/4/2015 10:22:49 AM
Dr. George Lasezkay Joins Acucela as Executive Vice President, Legal Affairs 8/25/2015 9:30:22 AM
Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine 8/6/2015 11:37:57 AM